INTRODUCTION
The coordination of an efficient anti-tumor immune response requires the recognition of tumors and subsequent induction of innate and adaptive immune responses, which are critical for the successful eradication of tumors. DCs are pivotal part of immune system by virtue of their high Ag-presentation functions.
DCs are found at various anatomical locations as different subsets and maintain immunological homeostasis by sampling self-Ags (Banchereau and Steinman, 1998) . DCs rapidly infiltrate in tumor mass (Bergeron et al., 2006; Preynat-Seauve et al., 2007; Stary et al., 2007) . Clinically, an increased number of tumor-infiltrating DCs have been reported to correlate with a better prognosis in cancer patients (Kobayashi et al., 2007; Lesimple et al., 2006; Thomas-Kaskel et al., 2007; Osada et al., 2004) and DCs based immunotherapy is highly effective for the inhibition of tumor metastasis or recurrence (Chang and Dhodapkar, 2003; Lim et al., 2007) .
Large number of animal and human studies has shown that Ag-loaded DCs lead to anti-tumor immune responses with tumor regression and rejection (Schott, 2006) . DCs exhibit anti-tumor function by their specific T cell regulatory capacity (Lanzavecchia and Sallusto, 2001) , which is generated by the presentation of tumor Ags upon DCs maturation (Nouri-Shirazi et al., 2000; van den Broeke et al., 2003) . Earlier evidences have also shown that DCs mediated anti-tumor responses are associated with its 'adjuvant function' by stimulating cytotoxic T cell responses (Mayordomo et al., 1995; Zhang et al., 2007b) and Thl-mediated tumor immunity (Hokey et al., 2005) .
Recent reports have revealed that DCs can directly induce tumor cell death (Trinite et al., 2005) . Overwhelming evidences have accumulated in favour of DCs mediated T cell independent anti-tumor immune response to execute tumor (Lee et al., 2007) . Human umbilical cord blood DCs kill tumor cells without damaging normal hematological progenitors (Shi et al., 2005) . Tumoricidal potential of blood DCs have been recently demonstrated (Schmitz et al., 2005) . DCs induce the death of human papilloma virustransformed keratinocytes but not of normal keratinocytes, suggesting their killing specificity against pre-neoplastic cells (Hubert et al., 2001 ) . Human DCs mediated cytotoxicity against breast carcinoma is also reported (Manna and Mohanakumar, 2002) .
In-vitro growth inhibition of a broad range of tumor cell lines by activated human DCs has been observed (Chapoval et al., 2000) . Mouse and human DCs also become cytotoxic DCs trigger NO mediated tumor cell death upon LPS or IFN-y treatment (Nicolas et al., 2007) . TNFa release has also been proposed as a killing factor against TNF-sensitive cancer cells by DCs (Chapoval et al., 2000; Vanderheyde et al., 2001 ).
Direct tumor recognition and killing through TRAIL, PAS-ligand, lymphotoxin a1~2, ·and NKR-P1 receptors have been reported (Lu et al., 2002; Trinite et al., 2000) . Human
MOs-derived DCs exhibited potent lytic activity towards various human tumor cell lines of distinct origin (Janjic et al., 2002; Yang et al., 2001) . Recently Stary, G., etal have also reported that DCs loaded with cytotoxic proteins (perf orin, granzyme ), act as weapons of tumor mass destruction in-vivo; they have demonstrated that skin tumors (basal cell carcinomas) regress when smeared with Imiquimod, a drug that activates DCs through TLRs (Stary et al., 2007) . Recent reports also demonstrate that 'like NK cells' DCs kill tumors that lack MHCI. It has been demonstrated that 'like T cells' pDCs specifically destroy tumor cells in-vitro. Thus varied target specificity implies that DCs have intrinsic capacity to kill all kinds of tumor cells (Bashyam, 2007; Stary et al., 2007) .
Rat cytotoxic DCs express NKR-P2/NKG2D activating receptor (Alli et al., 2004) .
NKR-P2 is an ortholog of human and mouse NKG2D. NKG2D is a 24.4-kDa disulfide linked homodimer belonging to type-II c-type lectin like receptor also expressed on NK cells (Alii et al., 2004) CD4+, CD8+ a~, yo+T cells (Coudert and Held, 2006) . Transcript of NKR-P2 has been shown on rat CD4+/CD8+ MOs (monocytes) and M¢ (Baba et al., 2006) . Recently NKG2D was also reported on a cytotoxic subset of mouse DCs (Taieb et al., 2006 , Chan et al., 2006 , human myeloblastic KG 1a cells (Guilloton et al., 2005) , that recognizes various stress inducible ligands on tumor cells and generates effective immune response (Raulet, 2003) .
DCs maturation is characterized by the modulation of distinct surface receptors and differential capacity of Ag processing and presentation (Banchereau and Steinman, 1998) .
Activation and maturation associated fine reprogramming of DCs against neoplastic cells is also exerted through apoptotic and necrotic cells tumor cells (Demaria et al., 2005 , Sauter et al., 2000 . Enhancement of immune response by cross-linking specific receptors on immune cells has emerged as a potential therapeutic tool in cancer treatment (von Mehren et al., 2003) . Antibody mediated activation and maturation of DCs have been reported by crosslinking Fey (Kalergis and Ravetch, 2002), CD32 (Banki et al., 2003; Corinti et al., 1999; Fedele et al., 2004 ), CD38 (Fedele et al., 2004 ), CD40 (Caux et al., 1994 -DC receptors (Blocki et al., 2006) . Previously, it was reported that splenic DCs undergo maturation after coculture with fixed AK-5 tumor cells (Alli and Khar, 2004 ) and a direct involvement of NKR-P2 in the induction of DCs mediated anti-tumor immune response was shown (Alli et al., 2004) . These observations suggest that stimuli dependent concerted antitumor responses can be utilized to comprise DCs as potential immunotherapeutic agents.
In the present study we show the expression of NKR-P2/NKG2D on DCs isolated from various anatomical locations. We demonstrate that cross-linking of NKR-P2 with an agonistic NKR-P2 mAb (1A6) on rat DCs provides a strong stimulatory signal, which in tum enhances apoptosis in tumor targets through NO and also induces cytostatic effect on tumor growth. 1A6 mediated DCs activation is dependent on p38, PI3K, ERKl/2, PKC (protein kinase C), NF-KB translocation and Ca ++ mobilization, suggesting the involvement of MAPkinase pathway in NKR-P2 mediated DCs activation. Interestingly, 1A6 also transmits the effective maturation signal in DCs, which is characterized by enhanced MHC II, B7-2, CDla expression, Ag presentation function and reduced endocytic capacity of DCs. Besides, 1A6 also induces DCs to secrete Thl immunoregulatory cytokines.
AK-5 tumor is a highly immunogenic rat histiocytoma that regresses spontaneously upon s.c. transplantation in syngenic animals, whereas it kills 100% hosts upon i.p.
transplantation (Khar et al., 1998) . We show that IA6 administration in-vivo induces activation and maturation of DCs, resulting in faster regression of AK-5 tumor (s.c. and i.p.).
The present study demonstrates the stimulatory potential of anti-NKR-P2 mAb and mechanism of NKG2D/NKR-P2 mediated tumor cell death, which could be utilized to enhance the therapeutic capability of DCs for successful treatment of cancer.
RESULTS

Expression of NKR-P2/NKG2D on DCs
First we examined the phenotypic profile of freshly isolated splenic DCs (SDCs) and peritoneal DCs (PDCs) to assess the purity of the cell population with specific antibodies against as-integrin, MHC II, CDllc, ICAM-I, B7-2, which are the markers of DCs; no contamination of NK cells (CD16+), or M</> (EDI+) were found in DCs preparations (Fig. 3.1A) .
NKR-P2/NKG2D expressing rat NK cells, RNK-16 cells, CDS+ T cells and Bone marrow derived DCs (BMDCs) were stained with mAblA6, which showed expression of NKR-P2 on rat BMDCs (Fig 3.1B) . Similarly, mouse NK cells, activated CDS+ T cells and mouse BMDCs were stained with mAblA6 and polyclonal anti-NKG2D Ab (Fig 3.1C) .
NKR-P2/NKG2D expression on rat BMDCs and SDCs was also confirmed by staining of CD11c+ DCs (Fig3.2A) . We also determined the proportion of NKR-P2 expressing DCs, isolated from spleen, peritoneal cavity and BMDCs. ac-integrin positive BMDCs, PDCs and SDCs were positive for NKR-P2, which was determined after staining with mAblA6 ( Fig. 3.2B ).
Activation of DCs with mAb 1A6 in-vitro
In order to check the activation of DCs from different sites with agonistic anti-NKR-P2 mAb (1A6), pure populations of BMDCs, PDCs and SDCs were incubated with Isotype control Ab, mAblA6, fixed BC-S tumor cells and LPS for 24 h. NO produced in response to NKR-P2 cross-linking from BMDCs, PDCs and SDCs was estimated. About 6~ 7 fold increase in NO levels was observed with BMDCs and PDCs, whereas ~2 fold increase was detected from SDCs in-vitro. Coculture of fixed BC-8 tumor cells with DCs (25: 1) and LPS (1 jlg/ml) stimulation was used as positive controls in the assays. In parallel assays peritoneal Mc/>s do not show activation with similar stimuli except LPS (Fig. 3.3A) .
We also determined if in-vivo administration (i.p.) of mAblA6 induced the activation of PDCs and SDCs. PDCs and SDCs were harvested after 36 h of 1A6 injection and treated again with mAb 1 A6 as second dose of activator or left untreated for 24 h. About 6-fold increase in NO production was observed from 1A6-injected PDCs, which increased further upon second dose of 1A6 stimulation in-vitro. However, SDCs isolated from 1A6 injected animals produced ~2.5 fold more NO in comparison to control, whereas second dose of 1A6 (in-vitro) to SDCs further enhanced the NO secretion significantly. LPS was also used as second activator (Fig. 3.3 
B, C).
We have also estimated tumoristatic potential of IA6 activated PDCs and SDCs.
PDCs and SDCs from IA6-injected rats were able to suppress growth ofBC-S tumor cells significantly in-vitro (Fig.3.4 A, B) . Growth of BC-8 cells alone was slightly inhibited in the absence of 1 A6 treated DCs.
The cytostatic effect of IA6-activated PDCs was higher than SDCs upon in-vitro activation. Tumor growth inhibition was significantly enhanced when assay was performed with in-vivo primed cells; and inhibition was comparable for PDCs and SDCs when tumor B. NKR-P2 expression on rat immature BMDCs, PDCs and SDCs. The results shown are of a£-integrin and NKR-P2/NKG2D positive DCs. Anti-NKR-P2 mAb was probed with alexa-594 (Fl 2 H-signal) followed by staining with anti-a£-integrin mAb (OX-62), OX-62 Ab was probed with alexa-488 (Fl 1 H-signal). 
1A6 mimics NKR-P2 ligand for DCs
To check whether mAblA6 binds to NKR-P2/NKG2D and mimics its ligand, we performed the 1A6 binding assays upon NKG2D pre-blocking. A significant decrease in binding of 1A6 was observed with goat anti-NKG2D polyclonal Ab on SDCs ( Fig. 3.5A ).
Similarly, a significant decrease in activating potential of mAblA6 was also observed upon blocking the NKR-P2/NKG2D with bivalent anti-NKG2D polyclonal Ab as found by decreased NO production ( Fig. 3 .5B).
1A6 fails to activate NK cells and macrophages in-vivo
Our earlier observation (Alli et al., 2004) shows that IA6 acts as a blocking Ab for NK cells under in-vitro conditions. We further checked the NK cell activation with IA6 invivo, but could not find the upregulation of FasL and IFN-y on splenic NK cells confirming no activation of NK with 1A6 ( Fig. 3 .6A). Similarly, iNOS and TNF-a levels remained unchanged in splenic M¢ upon IA6 injection ( Fig. 3 .6B).
No endotoxin contamination in 1A6 mAb
To rule out the possibility of endotoxin contamination in mAblA6 preparation, we performed LAL assays and the endotoxin contamination was always below the permissible limits (less than 0.125EU). Furthermore, boiling of 1A6 (100°C, 20 min) completely abrogates its activity whereas retains its potential upon polymyxin-B (50 J...Lg/ml) treatment. In parallel assays LPS activity was significantly abrogated with polymyxin-B and remained unaltered upon boiling (100°C, 20 min) ( Fig. 3.7 ).
3.2.6 1A6 dependent tumor killing is mediated by Nitric Oxide
To illustrate mAb 1A6 mediated DCs activation and tumor cell killing, we have studied activation of immature BMDCs with 1A6. .c E (lmg/ml/ratlday, 5-injections each in 3 rats were given along with appropriate controls). Appropriate secondary Ab (alexa-488) was used to probe the specific staining. Anti-NKR-P2 mAblA6 preparation is free of endotoxin contamination. BMDCs produce NO upon stimulation with 1A6. BMDCs were stimulated with 1A6 and LPS. 1A6 in presence of 50 )Jg/ml peptide-polymyxin B (PMB) and heat-denatured 1A6 form (100°C, 20 min) were used as BMDC stimulators. Upon boiling agonistic nature of IgM-1A6 was completely abrogated due to its proteinaceous nature, whereas polymyxin B failed to neutralize its agonistic nature. In the parallel assay heat inactivation did not inhibit LPS activity significantly, which was significantly brought down with PMB-neutralized LPS. Representative bar diagram is indicative of several experiments that were carried out to ensure no endotoxin contamination in 1A6, which was purified with ammonium sulphate precipitation and protein A sepaharose affinity column throughout the study. A and B. Upregulation of iN OS transcript and protein upon NKR-P2 crosslinking with 1A6. Day6 attached BMDCs were incubated with isotype control rnAb or with 1A6 for 24 h. Total RNA and proteins were isolated from similar experimental set up and subjected to RT-PCR (using iNOS specific primers) and immunoblotting (using rabbit anti-mouse iNOS Ab). GAPDH and ~-Actin detection were used to ascertain equal amount of eDNA template and protein in RT-PCR and immunoblotting. Fixed BC-8 cells (at 25: 1 ratio) in coculture with attached BMDCs and LPS (1 )lg/ml) were used as positive controls for iNOS induction in attached BMDCs.
As a result of iN OS induction, 6~ 7 fold increase in NO content was observed in IA6 treated BMDCs. NO secretion was significantly abrogated upon pretreatment ofBMDCs with irreversible iNOS inhibitor Wl400. Similarly, NO levels in BC-8 and LPS treated BMDCs were also inhibited with Wl400 (Fig. 3.9A) . Furthermore, we also determined the cytostatic activity of 1A6-activated BMDCs. 
NKR-P2 cross-linking activates p38K, AKT, ERK and translocation ofNF-K.B
To determine the signaling pathways involved in the production of NO upon 1A6 cross-linking in BMDCs, we measured NO content in PD98059, Ly294002 and SB203580 treated BMDCs along with experimental controls and found a significant reduction in NO production with these inhibitors, which confirms the involvement of MAP kinase in 1A6 mediated BMDCs activation. Significant inhibition of NO production was also observed with Ca 2 + chelator EGTA, protein kinase C inhibitor, H7 and with protein tyrosine kinase inhibitor, Genistein (Fig. 3.11A ).
We further studied the effect of PD98059, Ly294002 and SB203580 on iNOS levels.
Significant inhibition of iNOS expression was observed upon pretreatment of BMDCs with
ERKl/2 inhibitor PD98059, AKT kinase inhibitor Ly294002 and only a slight do.wilrei~iation of iN OS was observed with p38 kinase inhibitor SB203580 (Fig. 3.11B ).
We have further examined phosphorylation kinetics of p38, AKT and ERKl/2 upon 1A6 cross-linking and compared it with LPS mediated signal transduction at similar time points by immunoblotting. Upon 1A6 stimulation, maximum pP38 was found at 45-60 min, whereas LPS caused significant phosphorylation at 10 min. Both 1A6 and LPS mediated p38 phosphorylation was inhibited by imidazole SB203580. However, complete inhibition was A. NO secretion upon NKR-P2 cross-linking was inhibited with W1400. Day6 attached BMDCs were pretreated with W1400 (5J.1M, 45min) afterward stimulated with mAb 1A6. Fixed BC-8 cells (at 25:1 ratio) and LPS in the absence or presence ofW1400 were also used as positive control. Cell free culture supernatants were collected from triplicate experimental setup after 24 h and NO content was measured by Griess reagent.
B.
Cross-linking of NKR-P2 on BMDCs mediate cytostatic action through NO. BMDCs were pretreated with W1400 (5J.1M, 45min) and stimulated with mAb 1A6 for 6 h along with experimental controls as indicated in the figure. Subsequently, BMDCs were co-incubated with live BC-8 tumor cells (doubling time 16 h) for 36 h. eH] Thymidine was added 10 h before tumor cell harvesting. A. Effect of pharmacological inhibitors PD98059, Ly294002, SB203580, EGTA, H7 and Genistein on 1A6 induced NO production by BMDCs. Attached day 6 BMDCs were treated with PD98059 (20 11M), L Y294002 (50 11M), SB203580 (10 11M), EGTA (2mM), H7 (10 11M), Genistein (lO!lM) or medium alone for 1 h before stimulation with mAb 1A6 (100 1-1g/ml). After further 24 h incubation, cell free culture supernatants were collected and NO content was measured by Griess reagent.
Effect of PD98059, LY294002 and SB203580 on mAb 1A6 induced iNOS expression. BMDCs were pretreated with or without PD98059 (20 11M), SB203580 (10 11M) or LY294002 (50 11M) for 1 h before stimulation with mAblA6 for 12 h. Celllysates were analyzed by immunoblotting using rabbit anti-mouse iNOS Ab.
observed in the case of 1A6 at 60 min. Chomone Ly294002 is a specific inhibitor of PB kinase and blocks activation of AKT kinase. pAKT form was significantly upregulated at 45 min upon 1A6 cross-linking as well as by LPS treatment. Ly294002 completely abrogated the 1A6 mediated AKT phosphorylation at 60 min and a significant blocking was also observed in LPS mediated activation (Fig. 3.12) . .
The ERK pathway is known to be important in many cell types as regulator of cell survival. ERKl/2 phosphorylation was detected within 10 min after 1A6 or LPS stimulation.
LPS induced stronger activation of ERK2 at 60 min and 1A6 induced ERKl activation strongly till 45 min. Strong activation of both ERKl and ERK2 was observed at 45 and 60 min with LPS, whereas significant ERK2 activation was observed only at 60 min with 1A6.
However, flavanoid PD98059 inhibited significantly both ERKI/2 phosphorylations at 60 min ( Fig. 3.12 ).
NK-KB plays a significant role in DCs activation; therefore we have investigated the role of NF-KB in mAb 1A6 induced BMDCs activation. The transcription factor NF-KB is bound to IKB-a in the cytoplasm and retained there in an inactive form. LPS stimulation results in degradation of IKB-a and as a result free NF-KB translocates to the nucleus and activates transcription of various genes. IKB-a degradation was observed within 30 min upon LPS treatment. However, significant degradation of IKB-a was only observed at 60 min upon 1A6 cross-linking indicating similar but slow activation ofNF-KB with 1A6 in comparison to LPS (Fig. 3.13 ).
To confirm NF-KB translocation, nuclear extracts of stimulated BMDCs were immunoblotted with NF-KB p65. Upon LPS stimulation NF-KB was detected at 30 min, whereas in 1A6 stimulated cells, the band was detected at 60 min (Fig. 3.13) . Hence, IKB-a degradation correlates very well with NF-KB translocation and thus confirms the activational translocation. ,.....,_..._'""""'!!'!:'_. .
1A6 induces maturation of DCs and proliferation of autologous T cells
1A6 induces phosphorylation of p38K, AKT and ERKl/2. BMDCs were treated with 1 A6 ( 100 ).!g/ml) or LPS ( 1 ).!g/ml) separately and subjected to immunoblotting with specific Abs (control and phospho-form specific Ab). As indicated in the Figure, attached BMDCs were pretreated with SB203580 (upper panel), Ly294002 (middle panel), and PD98059 (lower panel) for 45 min before exposure to 1A6 or LPS. The panels show detection of phosphorylated form of pp38, pAKT and pERK1/2 along with unphosphorylated forms p38, AKT and ERKl /2 as controls at different time intervals (0, 10, 30, 45, 60 min) along with inhibitors. Inhibitor treated BMDCs were loaded in right most well as indicated in figure. For the detection of total form and phosphorylated form of kinases the protein samples were loaded in parallel wells in equal amount. LPSI -. .
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Role of NF-KB in 1A6 induced BMDC activation. 1A6 treatment induces the degradation of lK-Ba in immature BMDCs. Attached BMDCs were treated with 1A6 (100)lg/ml) and LPS (l)lg/ml) for different time points (0,30,45 ,60, 120,240 min) as indicated in figure, total cellular protein was run on SDS-PAGE followed by protein transfer to membrane. lK-Ba signal was detected with specific mAb, along with detection of P-actin, as equal loading control for total protein. From the similar experimental setup nuclear extracts from attached BMDCs were prepared and subjected to immunoblotting with rabbit anti-NF-KBp65 polyclonal Ab (lower panel). Ponceau S blot of the nuclear extract from IA6 treated BMDC is shown as the equal loading control.
Similarly B7.2 levels were increased from 22% to 96% for BMDCs and 44% to 97% for SDCs. Upon 1A6 cross-linking CDla expression was also enhanced from 5% to 22% for BMDCs and 11% to 25% for SDCs. Coculture of adherent BMDCs and SDCs with fixed BC-8 tumor cells at 1:25 ratio also induced upregulation of MHC II, B7-2 and CD1a and was used as positive control to assess maturation (Fig. 3.14) .
After evaluating the phenotypic maturation of BMDCs and SDCs, we tested the ability of BMDCs and SDCs to stimulate T cell proliferation in an autologous MLR assay.
BMDCs and SDCs with isotype mAb exhibited a higher T cell proliferation activity. Upon 1A6 cross-linking ~3 fold proliferation was detected with BMDCs, whereas ~ 4 fold proliferation was recorded with SDCs. Stimulatory capacity of 1A6 was significantly inhibited upon 1A6 neutralization with recombinant rNKR-P2 protein for both BMDCs and SDCs. rNKR-P2 protein did not induce stimulation of BMDCs (Fig. 3.15A ). The T-cell stimulatory capacity of SDCs was found to be higher than BMDCs. To exclude the possibility of a direct action of 1A6 on T cells, autologous T cells treated with 1A6 were also used as responder in MLR assay. Cellular aggregation in response to surface Ags signaling is a synchronized process and essential for cell-cell interaction and adhesion. Upon treatment of lA6 both BMDCs and SDCs undergo homotypic clustering. BMDCs cultures led to formation of large homotypic clusters, whereas SDCs showed comparatively smaller homotypic clusters in 6 h. This phenomenon was not observed with Isotyope-matched mAb ( Fig. 3.15B ).
Role of p38 MAPK, AKT and ERK pathways in 1A6 mediated DCs maturation
To investigate the role of MAPK signaling pathway in 1A6 induced BMDCs maturation, we pretreated BMDCs with PD98059, Ly294002 and SB203580 and evaluated expression profile of MHC II and B7-2 upon 1A6 treatment using double staining. A 23% reduction in MHC II/ B7-2 expression was found with ERKl/2 inhibitor on BMDCs.
Ly294002 inhibited double staining to 37% on BMDCs. SB203580 inhibited expression to 35% on BMDCs (Fig. 3.16A ). Taken together, these results suggest involvement of MAP kinase signaling in 1 A6 mediated DCs maturation.
3.2.10 1A6 cross-linking reduces endocytic capacity of DCs iDCs possess high endocytic capacity whereas upon maturation, the endocytic function is reduced and the Ags presentation function increases. We have evaluated the effect of 1A6 treatment on endocytosis by monitoring uptake of Zymosan-FITC in SDCs. At 4°C the endocytic capacity is inhibited, however, at 37°C both untreated and isotype control A. 1A6 enhances the capacity ofDCs to activate T cells. BMDCs and SDCs were treated with 50 j.lg/ml of 1A6; 50 j.lg/ml 1A6 + 50 j.lg/ml rNKR-P2 and 50 j.lg/ml rNKR-P2 protein alone for 24 h. Activated DCs along with experimental controls were incubated with autologous CD3+ splenic T cells at 1:20 (DC: T) ratio. eHJ Thymidine was added 12 h before harvesting of T cells that were incubated for 36 h with activated DCs. After T cells harvesting on silicone membrane the proliferation index was counted in (3-counter with enhancer-cocktail. Results are shown as mean cpm x 10 3 ± SD, and are representative of 3 similar experiments. B. Anti-NKR-P2 mAb 1A6 enhances homotypic clustering in DCs. Nonadherent BMDCs and SDCs were incubated with isotype control mAb or with 1A6 or left untreated for 6 h and then photographed at 40X in 6-well culture plates after mild-shaking. As observed in photograph, 1 A6 treatment induces homotypic (association of similar cell type) clustering in nonadharent DCs. 
BC-8 LPS
A. Effect of PD98059, LY294002 and SB203580 on 1A6 induced upregulation of maturation markers on BMDCs. Immature day6 BMDC were pre-treated with the inhibitors (PD98059, L Y294002 and SB203580) for 45 min, and stimulated with isotype control mAb and mAb 1A6 for 24 h. DCs were fixed in 1% formaldehyde and probed with mouse anti-MHC II mAb and rat anti-B7-2 mAbs simultaneously. Anti-mouse alexa-594 was used for detection of MHC II signal (FhH) and anti-rat alexa-488 was used for the detection of B7-2 (FbH) by FACS. Double staining in the figure shows the surface expression of MHC II and B7-2 and its inhibition with respective inhibitors. Numbers in the figure denote the % positive population in the upper right quadrant.
B. Downregulation of endocytosis by DCs upon NKR-P2 cross-linking with 1A6. Attached SDCs were incubated with isotype control mAb, 1A6, with fixed BC-8 cells (25: 1 ratio) and LPS for 24 h. DCs were harvested, washed with PBS and analyzed for Zymosan-FITC uptake. Harvested DCs were incubated with Zymosan-FITC (1 mg/ml) at 37°C (in C0 2 incubator) or at 4°C (in ice) for 60 min in incomplete media, in 1.5ml eppendorftubes. After washing with chilled PBS 5-times, cells were analyzed by F ACS to measure specific uptake of Zymosan-FITC and non-specific binding of Zymosan-FITC to DCs. treated SDCs showed significant uptake, whereas cross-linking ofNKR-P2 with 1A6
inhibited the Zymosan-FITC uptake. Similar inhibition of endocytosis was observed upon coculture of SDCs with fixed BC8 tumor cells. LPS matured SDCs were used as positive control in the assay (Fig. 3.16B ).
1A6 triggers synthesis of inflammatory cytokine by DCs
DCs maturation stimuli are known to induce the secretion of inflammatory cytokines, such as IL-12, TNF-a, IFN-y and IL-l~. Low concentration ofcytokines was detected in the culture supernatants of BMDCs and SDCs. Upon 1A6 stimulation in-vitro significantly higher amounts of IL-12, IFN-y and IL-1~ were produced by BMDCs, whereas SDCs produced IL-12, IFN-y, IL-l~ and TNF-a also. Isotype matched control mAb failed to stimulate BMDCs and SDCs under similar conditions. Upon coculture with fixed BC-8 cells significantly higher levels of these cytokines were produced by both BMDCs and SDCs (Table 3 .1). Cytokine elevation was also confirmed by semiquantitative RT-PCR for both
BMDCs and SDCs (Fig. 3.17) .
Immunotherapeutic potential of 1A6 in anti-tumor responses
To investigate functional status of DCs in-vivo 1A6 was injected in normal rats.
1A6 injected OX62 positive SDCs were found to possess enhanced expression of iNOS and B7-2 (Fig. 3.18A) , which demonstrates higher activation status of DCs in-vivo and therefore could be responsible for faster regression of transplantable tumor.
To evaluate the therapeutic potential of agonistic 1A6, we examined its anti-tumor activity in AK-5 tumor regression model. Rats were implanted with 3 x 10 6 tumor cells at s.c. site and tumor growth was monitored till its complete regression. Interestingly coadministration of 1A6 either by s.c. or i.p. along with 3 x 10 6 tumor cells (s.c.) resulted in slow growth and faster regression of the tumor. 1A6 mediated rapid regression of tumor was also found to be associated with the appearance of early necrotic spots on solid tumors (Fig. 
3.18B).
AK-5 is highly virulent upon i.p. transplantation and leads to 100% mortality of rats (Khar et al., 1998) . 1A6 co-administration (i.p./s.c.) cured 60% of animals and showed delayed death in 40% rats, whereas all control animals died by early ascites development 
IL-12
'~·- A. Effect of 1A6 on rats challenged with AK-5 tumor (i.p., 4x 10 6 cells/rat). Rats were given 3 prior injection of 1A6 (lmg/ml/rat) before transplantation of AK-5 cells and 9-1A6 injections after transplantation. Host death was monitored regularly, no tumor cells were found in 60% of rats, which was confirmed by the examination of the ascitic fluid. B. Effect of 1A6 on rats challenged with ZAH tumor (i.p., 2x 10 7 cells/rat). Rats were given 2 prior injections of 1A6 (lmg/ml/rat) and challenged with ZAH hepatoma upon 1A6 coadministration (6 injections). Animals were routinely monitored for host death and tumor growth. A prolonged survival of rats was found in 1A6-injected animals. 10 animals per group were used for this study. NF-KB activation plays a pivotal role in iNOS induction and DCs maturation, thus governs both innate and adaptive immunity. Cytotoxic NO production after 1A6 treatment represents strong induction of iN OS and iNOS induction is reported to be regulated by NF-KB activation. Furthermore, NF-KB acts as a potential transcription factor in the initiation of MHCII, CD86, and CD80 upregulation, as well as in IL-12 and TNF-a production (Bonizzi and Karin, 2004; Xie et al., 1994; Yoshimura et al., 2001 ) . We have observed degradation of IKB and translocation of NF-KB upon 1A6 cross-linking. NF-KB translocation to the nucleus has also been observed upon NKG2D ligand stimulation ofNK cells (Regunathan et al., 2005) . Thus NF-KB activation confirms it to be the key executioner of activation upon NKR-P2 cross-linking in DCs also.
NKR-P2 is a maturation-associated receptor as its upregulation has been detected upon DCs activation with fixed BC-8 tumor cells, agonistic mAblA6 and also in DCs obtained from tumor bearing animals (Alii et al., 2004) . NKR-P2 engagement also enhanced upregulation of MHC II, CD86 and CDla, which are involved in Ags presentation function of DCs. 1A6 activated BMDCs and SDCs were also able to cause T cell proliferation in autologous MLR assays. However, SDCs were slightly more efficient which could be due to their maturational status. In readout, the endocytic capacity of 1A6 stimulated BMDCs and SDCs was significantly inhibited upon IA6 stimulation, which also suggests it to be a potent maturational stimulus. We have also detected homotypic aggregation of BMDCs and SDCs upon 1A6 stimulation. Cellular aggregation in response to surface Ags-signaling is a regulated process and important for cell-cell interaction.
Previously we have shown relocalization of NKR-P2 upon IA6 cross-linking in splenic DCs (Alii et al., 2004) , which suggests that DCs form strong cellular interactions with tumor cells during NKR-P2 interaction with its natural ligand on tumor cell surface. Similar clustering events have also been observed upon MHC II and CD43 cross-linking (Corinti et al., 1999; Lehner et al., 2003) that could drive the formation of "DCs-T" cell cluster to provide efficient stimulatory signal. In summary, our results demonstrate that anti-NKR-P2 mAb pulsed DCs induce both innate and adaptive immune responses. This study demonstrates specific targeting of the tumor recognition receptor on DCs, which only operates under stress conditions and recognizes multifarious ligands, displaying its efficiency in a broad range. Our results also suggest an important role for NKR-P2 expressed on DCs in stimulating the anti-tumor
Immune response and the potential use of a mAb against NKR-P2 in cancer immunotherapy.
